about
Prognostic value of histopathology and trends in cervical cancer: a SEER population studyPreoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: impact on the irradiated volume of small bowel.Imaging in radiotherapy.Health-related quality of life in survivors of stage I-II breast cancer: randomized trial of post-operative conventional radiotherapy and hypofractionated tomotherapy.Innovations in image-guided radiotherapy.Phase II study of helical tomotherapy in the multidisciplinary treatment of oligometastatic colorectal cancerShort course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trialScapula alata in early breast cancer patients enrolled in a randomized clinical trial of post-surgery short-course image-guided radiotherapy.A (short) history of image-guided radiotherapy.Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.Hypoxic tumor cell radiosensitization through nitric oxide.Gating and tracking, 4D in thoracic tumours.NF-kappaB inhibition impairs the radioresponse of hypoxic EMT-6 tumour cells through downregulation of inducible nitric oxide synthase.Activated macrophages as a novel determinant of tumor cell radioresponse: the role of nitric oxide-mediated inhibition of cellular respiration and oxygen sparing.Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial.Daily megavoltage computed tomography in lung cancer radiotherapy: correlation between volumetric changes and local outcome.Geometric accuracy of a novel gimbals based radiation therapy tumor tracking system.Setup accuracy of the Novalis ExacTrac 6DOF system for frameless radiosurgery.The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-gamma and inducible nitric oxide synthase.Macrophages enhance the radiosensitizing activity of lipid A: a novel role for immune cells in tumor cell radioresponse.Lipid a radiosensitizes hypoxic EMT-6 tumor cells: role of the NF-kappaB signaling pathway.Implementation of HybridArc treatment technique in preoperative radiotherapy of rectal cancer: dose patterns in target lesions and organs at risk as compared to helical Tomotherapy and RapidArcAn in-house developed resettable MOSFET dosimeter for radiotherapy.IFN-gamma+ CD8+ T lymphocytes: possible link between immune and radiation responses in tumor-relevant hypoxia.Phase II study of preoperative helical tomotherapy for rectal cancer.Tumor volume regression during preoperative chemoradiotherapy for rectal cancer: a prospective observational study with weekly MRI.Computer-aided analysis of star shot films for high-accuracy radiation therapy treatment units.Single fraction versus fractionated linac-based stereotactic radiotherapy for vestibular schwannoma: a single-institution experience.Phase II study of helical tomotherapy for oligometastatic colorectal cancer.Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy.Volumetric imaging by megavoltage computed tomography for assessment of internal organ motion during radiotherapy for cervical cancer.Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer.Prediction of response to neoadjuvant radiotherapy in patients with locally advanced rectal cancer by means of sequential 18FDG-PET.Assessment of intrafractional movement and internal motion in radiotherapy of rectal cancer using megavoltage computed tomography.Small airways function in breast cancer patients before and after radiotherapyMRI-based tumor inter-fraction motion statistics for rectal cancer boost radiotherapy
P50
Q33295075-FB7F6A70-CCEC-477C-9D90-9E587FC05206Q33410968-319D1541-99F8-4757-944D-D9312F4C65D9Q34038878-94212A7C-4054-4E0E-A8D6-792319ED9E1FQ34457957-2B409344-6D79-4172-BC1E-9CD8B242854BQ34717651-41FDD6B6-3E3B-42C9-AA8A-B1D040A73216Q35968430-A7D9253F-7D45-447F-9D85-1AE23BC3A113Q36202970-6A8F2DD4-B986-4E58-B022-7156C2B56D68Q36369650-F5CBF0B3-9132-4C01-829A-722A273FC3D3Q37033399-C1B3C691-6C57-4345-B04A-C49B24DD2EE1Q37129071-F7297F0C-6681-4697-9D8F-C91C06BE71D7Q37161558-A5FC8C5D-40AD-4C43-A0E7-16DE08C08908Q37776780-90C42267-BBE4-4D42-9891-9E9531792973Q38302304-1CDED9D2-8445-491A-AE66-CB889EFA052FQ39722740-283A2B05-E30B-4C1B-8249-01510F6D2E48Q39847699-9B992427-D55C-4064-B004-83974D45A17DQ39855880-65DAA7ED-091E-4B6E-8DC1-345B655D6B46Q39970757-F0CBA3E9-3CC8-4C88-91E7-B3254C09D181Q39978375-4A421EFC-C04C-4CAA-B357-8EC8D745F117Q40217016-B50A09D1-4A00-4E6F-ACD7-5E55F06EB618Q40513405-539FD226-5D8E-471C-B16E-F54BAB4E541EQ40628715-50862CBD-40FA-4F8D-B613-9C1B87836E6EQ41638103-09FF6BAB-917D-49B0-BE70-8A52107DC265Q42646335-FEA8E54E-8F46-4EEF-B580-A41A7F14425CQ45940696-D38DEE18-B6BF-4E63-BFBB-40520BCDFB92Q46975488-5A3C4F4B-CDC0-4888-8F19-19175F2E16AAQ47441754-350C2E7A-DFEB-42D0-8A3A-8C65AD0BC679Q48576236-EAC4D1D0-292D-44D6-919E-F55785224BFBQ50433557-3D384B9B-33F0-48B5-AB6F-2C59CEC5A951Q51756957-919A3A71-6DD2-48FD-8E41-4CF78A45BA1FQ51790338-07F71875-E2CE-4304-89CB-C496E5CB04E6Q53066554-EAAEFF65-E50D-49B1-9B3A-F12C70EF4FB5Q53153075-1E7B8E0C-1952-4B06-873F-5C13F59310CCQ53286660-3C8A7DF8-858D-49AA-91FA-4D665E75A480Q53413330-0CB3E5F1-F0C8-404F-AC70-4C40E8878233Q84841038-5850C581-BE8C-4230-A0C2-C54624E3818BQ93169426-E4E5DC75-2BA7-438F-8D62-4A707F12502D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark De Ridder
@ast
Mark De Ridder
@en
Mark De Ridder
@es
Mark De Ridder
@nl
Mark De Ridder
@sl
type
label
Mark De Ridder
@ast
Mark De Ridder
@en
Mark De Ridder
@es
Mark De Ridder
@nl
Mark De Ridder
@sl
prefLabel
Mark De Ridder
@ast
Mark De Ridder
@en
Mark De Ridder
@es
Mark De Ridder
@nl
Mark De Ridder
@sl
P1053
F-4794-2013
P106
P31
P3829
P496
0000-0003-4433-8807